Singapore, Feb. 27 -- Japanese pharmaceutical company Takeda has announced a strategic partnership with Biological E, a leading vaccines and biologics company in India, to manufacture Takeda's dengue vaccine, TAK-003.

The partnership marks a crucial step in the fight against the global public health threat of dengue fever, aligning with the disease-specific target set by the World Health Organization (WHO) to achieve zero case-fatality rate due to dengue by 2030.

The partnership will substantially enhance manufacturing capabilities to ensure a sustainable global supply of the vaccine. Biological E will scale up its production capacity to potentially reach 50 million doses annually, accelerating Takeda's efforts to manufacture 100 millio...